The Analgesic Efficacy and Safety of Loxoprofen Sodium Patch in Patients With Herpes Zoster
Condition(s) studied
Investigational drug(s) / intervention(s)
Conventional therapy group: In the conventional therapy group, treatments will include opioids, antiviral drugs and so on.
Loxoprofen sodium patch combined with conventional therapy group: In the loxoprofen sodium patch combined with conventional therapy group, apply the loxoprofen patch to the painful point near the herpes lesion. Use one patch per day, twice a day. In addition, the group will contain conventional treatment for HZ, except loxoprofen sodium patch, including opioids, antiviral drugs and so on.
Study summary
Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Topical NSAIDs offer a promising alternative by delivering localized analgesia with reduced systemic exposure. Therefore, investigators hypothesize that loxoprofen sodium patch may effectively reduce the severity of HZ pain without significantly increasing adverse events.
Eligibility
Primary outcome measure(s)
- the average numeric rating scale score over the past 24 hours, rated each morning upon awakening and average over 7 days. — At week 4 after experimental drug medication
The numeric rating scale (NRS) score is a way to quantify the degree of subjective feelings such as pain using numbers. Generally, 0 represents no pain, and 10 represents the most severe pain. A higher score indicates more severe pain.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Beijing Tiantan Hospital, Beijing, Beijing 100070 | Beijing | China | Recruiting |
More Beijing Tiantan Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07378059 on ClinicalTrials.gov ↗ ← All trials in China